Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Restoring endogenous muscle stem cell function as a treatment for Duchenne muscular dystrophy
FY 2020-21
Summary
Duchenne muscular dystrophy (DMD) is a lethal neuromuscular disorder caused by the loss or malfunction of a protein named dystrophin, which stabilizes muscle fibers during contraction. Muscle stem cells (MuSCs) are a type of adult stem cell that can repair and regenerate damaged muscle tissue through a process known as differentiation. However, without dystrophin, MuSCs do not differentiate properly and exhibit signs of biological aging, thus reducing their regenerative potential and contributing to the muscle degeneration in DMD. DMD therapeutics currently aim towards improving patient care, hoping to prolong survival by targeting all muscles in the body. However, none specifically target MuSCs. Intriguingly, in studies of cachexia, a muscle-wasting syndrome, treatment with low doses of drugs that inhibit the process of protein synthesis were found to improve muscle differentiation and function in mice. At low doses, these drugs eliminated factors that induce cachexia by sequestering them into aggregates within the cytoplasm of the cell, known as stress granules. Given that DMD MuSCs exhibit impaired differentiation, we reasoned that treating DMD MuSCs with low doses of these drugs may improve their ability to differentiate and hence their regenerative function. Indeed, our experiments show enhanced differentiation following treatment of healthy and DMD mouse muscle precursor cells. The goal of this research project is to continue investigating how these drugs improve muscle differentiation at the cellular level. These findings will enhance our understanding of the pathways that control muscle differentiation in healthy and DMD contexts. Our goal is to provide proof of concept for a new therapeutic approach to enhance muscle stem cell function in DMD.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449496
Name
Filippelli Romina L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Restoring endogenous muscle stem cell function as a treatment for Duchenne muscular dystrophy
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Duchenne Muscular Dystrophy; Muscle; Muscle Regeneration; Myogenesis; Satellite Cell; Translation
Abstract
Duchenne muscular dystrophy (DMD) is a lethal neuromuscular disorder caused by the loss or malfunction of a protein named dystrophin, which stabilizes muscle fibers during contraction. Muscle stem cells (MuSCs) are a type of adult stem cell that can repair and regenerate damaged muscle tissue through a process known as differentiation. However, without dystrophin, MuSCs do not differentiate properly and exhibit signs of biological aging, thus reducing their regenerative potential and contributing to the muscle degeneration in DMD. DMD therapeutics currently aim towards improving patient care, hoping to prolong survival by targeting all muscles in the body. However, none specifically target MuSCs. Intriguingly, in studies of cachexia, a muscle-wasting syndrome, treatment with low doses of drugs that inhibit the process of protein synthesis were found to improve muscle differentiation and function in mice. At low doses, these drugs eliminated factors that induce cachexia by sequestering them into aggregates within the cytoplasm of the cell, known as stress granules. Given that DMD MuSCs exhibit impaired differentiation, we reasoned that treating DMD MuSCs with low doses of these drugs may improve their ability to differentiate and hence their regenerative function. Indeed, our experiments show enhanced differentiation following treatment of healthy and DMD mouse muscle precursor cells. The goal of this research project is to continue investigating how these drugs improve muscle differentiation at the cellular level. These findings will enhance our understanding of the pathways that control muscle differentiation in healthy and DMD contexts. Our goal is to provide proof of concept for a new therapeutic approach to enhance muscle stem cell function in DMD.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Filippelli, Romina L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~